Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for adalimumab
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.18877
Abstract: Circulating concentrations of the split complement factor C5a are significantly increased in hidradenitis suppurativa (HS)1 . C5a exerts strong chemotaxis and activation of neutrophils at the inflammatory areas so that blockade may be a promising… read more here.
Keywords: c5a; hidradenitis suppurativa; efficacy complement; clinical efficacy ... See more keywords